Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer

Annals of Oncology

Volumn 15, Issue 7, 2004, Pages 1065-1071

  Di Cosimo, S ^a   Alimonti, A ^a   Ferretti, Gia ^a   Sperduti, I ^a   Carlini, P ^a   Papaldo, P ^a   Fabi, A ^a   Gelibter, A ^a   Ciccarese, M ^a   Giannarelli, D ^a   Mandala M ^b   Milella, M ^a   Ruggeri, E M ^a   Cognetti, F ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b TREVIGLIO HOSPITAL   (Italy)

Author keywords

Adjuvant chemotherapy; Amenorrhea; Early breast cancer; Menstrual cycle phase

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GONADORELIN DERIVATIVE; METHOTREXATE; TAMOXIFEN;

ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; EARLY CANCER; FEMALE; FOLLICULAR PHASE; HUMAN; INCIDENCE; LUTEAL PHASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MODULATION; MULTIVARIATE ANALYSIS; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AMENORRHEA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; ITALY; MENSTRUAL CYCLE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; TIME FACTORS;

EID: 4143052526     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh266     Document Type: Article

References (30)

1. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001; 344: 1997-2008.
2. Levine MN, Bramwell VH, Pritchard KI et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 2651-2658.
3. Bryce CJ, Shenkier T, Gelmon K et al. Menstrual disruption in premenopausal breast cancer patients receiving CMF (IV) vs AC adjuvant chemotherapy. Breast Cancer Res Treat 1998; 50: 284 (Abstr).
4. Nabholtz J, Pienkowski T, Mackey J et al. Phase III trial comparing TAC (docetaxel, oxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002; 21: 36a (Abstr 141).
5. Goldhirsch A, Gelber RD, Castigliore M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol 1990; 1: 183-188.
6. Hrushesky WJM, Gruber SA, Sothern RB et al. Natural killer cell activity: age, estrous-and circadian-stage dependence an dinverse correlation with metastatic potential. J Natl Cancer Inst 1988; 80: 1232-1237.
7. Love RR, Duc NB, Dinh NV et al. Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. J Natl Cancer Inst 2002; 94: 662-669.
8. Milella M, Nistico C, Ferraresi V et al. Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 248 premenopausal women. Breast Cancer Res Treat 1999; 55: 259-266.
9. Bennet JC. Inclusion of women in clinical trials. Policies of population subgroups. N Engl J Med 1993; 329: 288-292.
10. Bianco AR, Del Mastro L, Gallo C et al. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer 1991; 63: 799-803.
11. Pagani O, O'Neill A, Castiglione M et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998; 34: 632-640.
12. Balsari A, Casalini P, Tagliabue E et al. Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle. Am J Pathol 1999; 155: 1543-1547.
13. Poniatowski BC, Grimm P, Cohen G. Chemotherapy-induced menopause: a literature review. Cancer Invest 2001; 19: 641-648.
14. Castiglione-Gertsch M, O'Neill A et al. International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003; 95: 1833-1846.
15. De Matteis A, Montedoro D, Nuzzo F et al. Hormonotherapy with goserelin depot after adjuvant chemotherapy in premenopausal women with early breast cancer. Is there any benefit? Ann Oncol 1998; 9 (Suppl 4): 11 (Abstr 52).
16. Davidson NE, O'Neil A, Vukov A et al. Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101). Proc Am Soc Clin Oncol 2003; 22: 5 (Abstr 15).
17. Kurebayashi J, Sonoo H, Shimozuma K. Timing of surgery in relation to the menstrual cycle and its influence on the survival of Japanese women with operable breast cancer. Surg Today 1995; 25: 519-524.
18. Braverman AS, Sawhney H, Tendler A et al. Pre-menopausal serum estradiol (E2) levels may persist after chemotherapy (CT)-induced amenorrhea in breast cancer (BC). Proc Am Soc Clin Oncol 2002; 21: 42a Abstr 164.
19. Badwe RA, Wang DY, Gregory WM et al. Serum progesterone, at the time of surgery and survival in women with premenopausal operable breast cancer. Eur J Cancer 1994; 30A: 445-448.
20. Rose DP, Davis TE. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet 1997; 1: 1174- 1176.
21. Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr 2001; 30: 135-142.
22. Meirow D, Lewis H, Nugent D, Epstein M. Subclinical depletion of primordial reserve in mice treated with cyclophospamide: clinical importance and proposed accurate investigative tool. Hum Rep 1999; 14: 1903-1907.
23. Padmanabhan N, Wang DY, Moore JW, Rubens RD. Ovarian function and adjuvant chemotherapy for early breast cancer. Eur J Cancer Clin Oncol 1987; 23: 745-748.
24. Mehta RR, Beattie CW, Das Gupta TK. Endocrine profile in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 1992; 20: 125-132.
25. Heer K, Kumar H, Speirs V et al. Vascular endothelial growth factor in premenopausal women: indicator of the best time for breast cancer surgery? Br J Cancer 1998; 78: 1203-1207.
26. Meirow D, Epstein M, Lewis H et al. Administration of ciclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Hum Reprod 2001; 16: 632-637.
27. Hrushesky WJM, Vyzula R, Wood PA. Fertility maintenance and 5-fluorouracil timing within the mammalian fertility cycle. Reprod Toxicol 1999; 13: 413-420.
28. Vaskivuo TE, Tapanainen JS. Apoptosis in the human ovary. Reprod Biomed Online 2003; 6: 24-35.
29. Jarrell J, Lai EV, Barr R et al. Ovarian toxicity of cyclophosphamide alone and in combination with ovarian irradiation in the rat. Cancer Res 1987; 47: 2340-2343.
30. Morita Y, Perez GI, Maravei DV et al. Targeted expression of Bcl-2 in mouse oocytes inhibits ovarian follicle atresia and prevents spontaneous and chemotherapy-induced oocyte apoptosis in vitro. Mol Endocrinol 1999; 13: 841-850.